Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats

Veterinary Clinics of North America - Small Animal Practice

Volumn 34, Issue 1, 2004, Pages 271-289

  Beale, Brian S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANALGESIC AGENT; ASCORBIC ACID DERIVATIVE; BIOFLAVONOID; CHONDROITIN SULFATE; CHONDROPROTECTIVE AGENT; COLLAGENASE; CYTOKINE; DIMETHYL SULFONE; DIMETHYL SULFOXIDE; FREE RADICAL; GLUCOCORTICOID; GLUCOSAMINE; GLUCOSAMINE SULFATE; GLUTATHIONE; GLYCOSAMINOGLYCAN POLYSULFATE; HYALURONIC ACID; HYDROGEN PEROXIDE; LEUKOTRIENE; MANGANESE; METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; ONCOPROTEIN; PENTOSAN POLYSULFATE; SERINE PROTEINASE; STROMELYSIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ANIMAL CARE; ANIMAL DISEASE; ANIMAL FOOD; CARTILAGE CELL; CAT; CELL METABOLISM; CHONDROPROTECTION; DIET SUPPLEMENTATION; DOG; DOSE RESPONSE; EXERCISE; GOOD MANUFACTURING PRACTICE; INFLAMMATION; JOINT FUNCTION; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; QUALITY CONTROL; REVIEW; SURGICAL TECHNIQUE; SYNOVIAL FLUID; SYNOVIOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CAT DISEASES; CATS; CONSUMER PRODUCT SAFETY; DOG DISEASES; DOGS; HEALTH FOOD; OSTEOARTHRITIS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0742323757     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2003.09.008     Document Type: Review

References (68)

1. Anderson M.A. Oral chondroprotectant agents. Part 1 Compend Contin Educ Pract Vet 21 7 1999 601-609
2. Boothe D.M. Drug management of osteoarthritis (parts 1 and 2) Proc TNAVC 1998 586-591
3. Boothe D.M. Nutraceuticals in veterinary medicine. Part 1 Compend Contin Educ Pract Vet 19 11 1997 1248-1255
4. McNamara P.S. Johnston S.A. Todhunter R.J. Slow-acting, disease-modifying osteoarthritic agents Vet Clin Small Anim 27 4 1997 863-867 951-2
5. Verbruggen G. Goemaere S. Veys E.M. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthrosis drug) in the treatment of finger joint, O.A Osteoarth Cartil Suppl A 1998 39-46
6. Bucsi L. Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis Osteoarth Cartil 6 Suppl A 1998 31-36
7. Adebowale A. Cox D. Liang Z. et al. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials JANA 3 2000 37-44
8. Beale B.S. Evaluation of active enzyme in six oral superoxide dismutase products Proc Vet Ortho Society 65 1998
9. Smith G. Influence of diet and age on subjective hip score and hip OA: a life long study in Labrador retrievers. Proceedings Veterinary Orthopedic Society, 2002.
10. Karzel K. Domenjoz R. Effect of hexosamine derivatives and uronic acid derivatives on glycosaminoglycan metabolism on fibroblast cultures Pharmacology 5 1971 337-345
11. Jimenez SA, Dodge GR. The effects of glucosamine on human chondrocyte gene expression. Proc 9th Eular Symposium, 1996. p. 8-10.
12. Hellio MP, Vigron E, Annefeld M. The effects of glucosamine on the human osteoarthritic chondrocyte. In vitro investigations. Proc 9th Eular Symposium, 1996. p. 11-2.
13. Basleer C. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro Osteoarth Cartil 6 6 1998 427-434
14. Du J. Adebowale A. Liang A. Eddington N.D. Bioavailability and disposition of the dietary supplements, FCHG49 glucosamine and TRH122 chondroitin sulfate in dogs after single and multiple dosing AAPS PharmSci Suppl 3 3 2001 W417
15. Davidson G. Glucosamine and chondroitin sulfate Compend Contin Educ Pract Vet 22 5 2000 454-458
16. Setnikar I. Giacchetti C. Zanolo G. Pharmakitetics of glucosamine in dog and in man Arzneim-Forsch/Drug Res 36 4 1986 703-705
17. Setniker I. Giaccheti C. Zanolo G. Pharmacokinetics of glucosamine in the dog and in man Arzneimittelforschung 36 1991 729
18. Vaz A.L. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in outpatients Curr Med Res Opin 8 1982 145-149
19. Hungerford D. Navarro R. Hammad T. Use of nutraceuticals in the management of osteoarthritis JANA 3 1 2000 23-27
20. Leffler C.T. Philippi A.F. Leffler S.G. et al. Glucosamine, chondroitin and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study Mil Med 164 2 1999 85-91
21. Das A.K. Hammad T.A. Efficacy of a combination of FCHG49™ glucosamine hydrochloride, TRH122™ low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis Osteoarthr and Cartil 8 5 2000 343-350
22. D'Ambrosio E. Casa B. Bompani R. et al. Glucosamine sulfate: a controlled clinical investigation in arthrosis Pharmacotherapeutica 2 8 1981 504-508
23. McNamara P.S. Barr S.C. Erb H.N. Hematologic, hemostatic and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days AJVR 57 9 1996 1390-1394
24. Li Hirondel J.L. Double-blind clinical study with oral administration of chondroitin sulfate versus placebo in tibiofemoral gonarthrosis Litera Rheumatol 14 1992 77-82
25. Bourgeois P. Chales G. Dehais J. et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs 3×400 mg/day vs placebo Osteoarth Cartil 6 Suppl A 1998 25-30
26. Hulse D.S. Treatment methods for pain in the osteoarthritic patient Vet Clin Small Anim 28 2 1998 361
27. Lippiello L. Woodward J. Karpman R. et al. Chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate Clin Orth Rel Res 381 2000 229-240
28. McNamara P.S. Barr S.C. Erb H.N. et al. Hematologic, hemostatic and biochemical effects in cats receiving an oral chondroprotective agent for thirty days Vet Ther 1 2 2000 108-117
29. Kirker-Head R.P. Safety of an oral chondroprotective agent in horses Vet Therap 2 4 2001 345-353
30. Leeb B.F. Schweitzer H. Montag K. Smolen J. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis J Rheumatol 27 2000 205-211
31. Hansen R.R. Smalley L.R. Huff G.K. et-al. Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 cases Equine Pract 19 9 1997 16-22
32. Johnson K.A. Hulse D.A. Hart R.C. et al. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cranial cruciate transection model of osteoarthritis Osteoarth Cartil 9 1 2001 14-21
33. O'Grady CP, Marwin SE, Grande DA. Effects of glucosamine hydrochloride, chondroitin sulfate, and manganese-ascorbate on cartilage metabolism. Proceedings of the AAOS 68th Annual Meeting, 2001. p. 157.
34. Beren J. Hill S.L. Diener-West M. et al. The effect of pre-loading oral glucosamine/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats Experim Biol Medic 226 2 2001 144-152
35. Canapp S.O. McLaughlin R.M. Hoskinson J.J. et al. Scintographic evaluation of glucosamine HCL and chondroitin sulfate as treatment for acute synovitis in dogs AJVR 60 12 1999 1552-1557
36. Adebowale A. Du J. Liang Z. et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs Biopharm Drug Dispos 23 2002 217-225
37. Bui LM, Bierer TL. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs.
38. Simon S.R. Oxidants, metalloproteases and serine proteases in inflammation Proteases, protease inhibitors and protease-derived peptides 1993 Birkhauser Verlag Basel 27-37
39. Auer D.E. Ng J.C. Seawright A.A. Effect of palosein (superoxide dismutase) and catalase upon oxygen derived free radical induced degradation of equine synovial fluid Equine Vet J 22 1990 13-17
40. Ghosh P. Smith M. Wells C. Second-line agents in osteoarthritis In: Dixon J.S. Furst D.E. editors. Second-line agents in the treatment of rheumatic diseases 1993 p. 363-427 Marcel Dekker New York
41. Beale B.S. Goring R.L. Degenerative joint disease In: Bojrab M.J. editor Disease mechanisms in small animal surgery 1993 p. 727-736 Lea & Febiger Philadelphia
42. Impellizeri J.A. Lau R.E. Azzara F.A. A 14 week clinical evaluation of an oral antioxidant as a treatment for osteoarthritis secondary to canine hip dysplasia Vet Q 20 Suppl 1 1998 S107-S108
43. Kuck J.C. Mulnix J.A. Clinical evaluation of an antioxidant joint nutrient and relief of the signs of pain associated with osteoarthritis in the dog. Proprietary data 2001 Animal Health Options Golden (CO)
44. Mulnix J.A. Promotion study, canine formula. Proprietary data 2001 Animal Health Options Golden (CO)
45. Kuck J.C. Mulnix J.A. Clinical evaluation of an antioxidant joint nutrient and relief of the signs of pain associated with osteoarthritis and gait irregularities in the horse. Proprietary data 2001 Animal Health Options Golden (CO)
46. Jones W.E. MSM reviewed J Equine Vet Sci 7 2 1987
47. Budsberg S. Barteges J. Schoenherr W. Effects of different N6:N3 fatty acid diets on canine stifle osteoarthritis Proc Vet Ortho Society 2001 40
48. 2 synthesis in Chinese hamster ovary cell cultures Pharmacol Res Commun 15 1983 709-717
49. Altman R.D. Dean D.D. Muniz O.E. et al. Therapeutic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester Arthr Rheum 32 10 1989 1300-1307
50. Carreno M.R. Muniz O.E. Howell D.S. The effect of glycosaminoglycan polysulfuric acid ester on articular cartilage in experimental osteoarthritis: effects on morphological variables of disease severity J Rheum 13 3 1986 490-497
51. Hannen N. Ghosh P. Bellenger C. et al. Systemic administration of glycosaminoglycan polysulphate provides partial protection of articular cartilage from damage produced by menisectomy in the canine Ortho Research 5 1 1987 47-59
52. Altman R.D. Dean D.D. Muniz O.E. et al. Prophylactic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester Arthr Rheum 32 6 1989 759-766
53. Verbruggen G. Veys E.M. The effect of sulfated glycosaminoglycan on the proteoglycan metabolism of synovial lining cells Acta Rheumatol Belgica 1 1971 75-92
54. von der Mark K. Collagen synthesis in cultures of chondrocytes as effected by arteparon In: IX Europ cong rheumatol 1980 p. 39-50 Euler Basel
55. Nishikawa H. Mori I. Umemoto J. Influences of sulfaed glycosaminoglycans on hyaluronic acid in rabbit knee synovia Arch Biochem Biophys 240 1985 146-148
56. Smith M.M. Ghosh P. The effect of polysulfated polysaccharides on hyaluronate (HA) synthesis by human synovial fibroblasts Agents Actions 18 1986 55-62
57. Verbruggen G. Veys E.M. Treatment of chronic degenerative joint disorders with a glycosaminoglycan polysulfate In: IX Europ cong rheumatol 1980 p. 51-69 Euler Basel
58. Dettmer N. Nowack H. Raake W. Platelet aggregation by heparin and arteparon Munch Med Wschr 125 1983 540-542
59. de Haan J.J. Goring R.L. Beale B.S. Evaluation of polysulfated gllycosaminoglycan for the treatment of hip dysplasia in dogs Vet Surg 23 1994 177-181
60. Lust G. Williams A.J. Burton-Wurster N. et al. Effects of intramuscular administration of glycosaminoglycan polysulfates on signs of incipient hip dysplasia in growing pups Am J Vet Res 53 10 1992 1836-1843
61. Beale B.S. Clemmons R.M. Goring R.L. The effect of a semi-synthetic polysulfated glycosaminoglycan on coagulation and primary hemostasis in the dog Vet Surg 1990
62. Rashmir-Raven A.M. Coyne C.P. Fenwick B.W. et al. Inhibition of equine complement activity by polysulfated glycosaminoglycans Am J Vet Res 53 1 1992 87-90
63. Tsuboi I. Matsuura T. Shichijo et al. Effects of glycosaminoglycan polysulfate on human neutrophil function Japanese J Inflamm 8 1988 131-135
64. Read R. Cullis-Hill D. The systemic use of the chondroprotective agent pentosan polysulfate in the treatment of osteoarthritis- results of a double-blind clinical trial in dogs J Small Anim Pract 37 3 1996 108-114
65. Innes J.F. Barr A.R. Sharif M. Efficacy of oral calcium pentosan polysulphate for the treatment of osteoarthritis of the canine stifle joint secondary to cranial cruciate ligament deficiency Vet Rec 146 15 2000 433-437
66. Howard R.D. McIlwraith C.W. Sodium hyaluronate in the treatment of equine joint disease Compend Cont Educ 15 3 1993 473-481
67. Schiavinato A. Lini E. Guidolin D. et al. Intraarticular sodium hyaluronate injections in the pond-nuki experimental model of osteoarthritis in dogs. II. Morphological findings Clin Orthop 241 1989 286-299
68. Hulse DA, Hart RC, Beale BS, Slater M, Weeks B, Kochevar D. The effect of Cosequin in cranial cruciate deficient and reconstructed stifle joints in dogs.